• NeOnc Technologies Holdings, Inc. is trading 12.9% up at $5.09 today, after the Department of Health – Abu Dhabi granted Investigational New Drug (IND) status for NEO212.
  • This clearance allows for Phase 2 evaluation of NEO212, an orally administered perillyl alcohol-temozolomide carbamate conjugate for aggressive brain tumors, in the UAE.
  • The authorization marks NEO212's first international regulatory clearance, following the completion of Phase 1 clinical evaluation.